SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. engages in the design, manufacture, and launch of rockets and spacecrafts. It provides satellite communication services. The company was founded by Elon Reeve Musk on March 14, 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is driving massive market activity following its high-profile Nasdaq debut, with community members fiercely debating its trillion-dollar valuation against the company's ongoing lack of profitability. While some retail investors are treating the hype as a multi-generational growth play, others are expressing significant caution, framing the current trading environment as a high-stakes liquidity event prone to extreme volatility.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently experiencing significant market volatility as investors weigh its upcoming Nasdaq-100 inclusion against a liquidity rotation into the high-profile SpaceX IPO. While the community remains divided between those capitalizing on the Nasdaq-driven buying pressure and others bracing for a post-IPO cooling of the broader space sector, long-term investors are highlighting Rocket Lab's established launch cadence and backlog as key differentiators from its peers.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing significant volatility as investors weigh the resolution of its fee dispute with Publicis against broader concerns regarding the company's executive leadership and intense short-selling pressure. The community is heavily divided, with some traders viewing the current price as a generational buying opportunity, while others remain skeptical and frustrated by the stock's inability to sustain upward momentum.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is seeing high volatility as investors weigh its exposure to SpaceX, Anthropic, and OpenAI against the implications of an ongoing ATM offering and broader market rotation. Community sentiment is deeply divided, with many debating whether the stock is a strategic opportunity to acquire private assets at a discount to potential NAV, or if the stock is facing selling pressure as market participants shift capital toward direct exposure to the upcoming SpaceX IPO.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing significant volatility as market liquidity rotates into the high-profile SpaceX IPO, causing a sector-wide pullback despite upcoming satellite launch catalysts. While some investors are concerned about potential sector drag and aggressive institutional selling, others view the sharp decline as a strategic buying opportunity for a long-term play on direct-to-device broadband technology.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is currently trending due to a wave of positive analyst sentiment and price target upgrades following a strong earnings report that highlighted a shift to profitability and record platform engagement. Investors are actively debating the company's long-term growth as a streaming gatekeeper while monitoring technical levels for a potential breakout toward previous highs.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors react to positive Phase 1 clinical data for subcutaneous Briumvi in myasthenia gravis and a concurrent initiation of a Phase 2 trial. The stock is seeing high social media volume fueled by speculation about a potential buyout and community optimism regarding Briumvi's expanding market potential.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar is currently in focus as investors analyze the stock's significant indirect exposure to the upcoming SpaceX IPO, viewing it as a potential value proxy for the space sector. Community sentiment is deeply divided between long-term holders betting on the revaluation of EchoStar's satellite assets and SpaceX stake, and short-sellers who are expressing concerns over the company's debt load and capital structure.

Entrepreneurshares Series Trust - ERShares Private-Public Crossover ETF

XOVR is trending as investors debate its role as a proxy for SpaceX exposure, with community members actively comparing its private-public crossover structure to other vehicles like DXYZ and NASA. Sentiment remains polarized, as some shareholders express frustration over stagnant price action, while others highlight the long-term value proposition of gaining liquidity and venture-style access to private industry leaders.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending due to the company's decision to withdraw a stock offering, which has sparked intense community debate regarding management's strategic execution. Traders are actively discussing the impact of this move on short positions, potential future buyouts, and the company's long-term conviction, with many looking for stability amid market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About

Key PointsPfizer aims to enter the weight loss drug market, and one platform should be the workhorse of this effort...

Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?

Amvuttra's blockbuster growth is reshaping ALNY's revenue mix, and fresh ATTR-CM approvals can unlock an even larger market.

Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

Pfizer (PFE) closed the most recent trading day at $26.14, moving +2.11% from the previous trading session.

Why Pfizer Stock Popped Today

Key PointsRBC upgraded Pfizer stock today, removing its sell rating on the big pharma giant...

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Key PointsLexicon Pharmaceuticals focuses on precision medicines for chronic conditions, bolstered by significant revenue growth from its core drug programs...

Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?

MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.

Here are Wednesday's biggest analyst calls: Nvidia, Tesla, Cava, Netflix, Chipotle, Pfizer, Nike, SharkNinja & more

Here are the biggest calls on Wall Street on Wednesday...

Viral Influencer: How Bill Gates' Billions Shape US Medical Research

Viral Influencer: How Bill Gates' Billions Shape US Medical Research

 Authored by Paul D. Thacker via RealClearInvestigations,

Bill Gates has long been one of the most admired people in the world, especially since he stepped down from his role running Microsoft to devote himself and...

PFE Gets FDA Nod for Expanded Use of Hemophilia Drug Hympavzi

Pfizer wins FDA approval to expand Hympavzi's use in additional hemophilia A and B patient groups, including children with inhibitors.

The $100 Billion Oncology Opportunity Investors are Starting to Notice

Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade. $NTHI, $GSK, $NUVL, $PFE, $RHHBY, $BMY

This account has been verified as an official PFE representative.

Verified Account

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

SMMT Stock Surges Overnight: Cancer Drug Survival Win Raises The Bar As PFE, BMY, MRK Chase Keytruda's Successor

Equity

Bullish Sentiment

Track PFE stock price, charts, news and real-time market activity on Stocktwits. Join the PFE message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Pfizer Inc stock.

PFEPfizer Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PFE News